dr. mcgregor compares recent data with combinations in rcc
Published 6 years ago • 104 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:14
dr. mcgregor on the combination of atezolizumab and bevacizumab in rcc
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
1:47
dr. mcgregor on choosing a combination therapy regimen in advanced rcc
-
1:49
dr. mcgregor on new combinations with immunotherapy in rcc
-
1:23
dr. mcgregor on unmet needs in advanced rcc
-
2:20
dr. mcgregor on advances made in the adjuvant setting of rcc
-
1:23:33
fine-tuning the wave of innovation in rcc
-
55:12
selecting and sequencing targeted and immunotherapy regimens for patients with rcc
-
3:12
opdivo (nivolumab) the immunotherapy cancer treatment
-
3:29
other emerging combination approaches in rcc
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
0:53
dr. mcgregor on challenges facing frontline treatments for rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
1:08
dr. mcgregor on unmet needs in non-clear cell rcc
-
0:51
dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
-
1:35
dr. grigg on immunotherapy/tki combinations in rcc
-
5:56
recent data in the adjuvant setting of rcc
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
0:58
dr. chowdhury on separate roles of pazopanib and pembrolizumab in rcc
-
1:10
dr. motzer on first-line treatment of metastatic rcc